The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Fingerprint

Dive into the research topics of 'The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds